Post-effective Amendment to an S-8 Filing (s-8 Pos)
2018年7月21日 - 5:27AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on July 20, 2018
Registration
No. 333-165714
Registration
No. 333-168970
Registration
No. 333-172100
Registration
No. 333-180144
Registration
No. 333-188679
Registration
No. 333-196740
Registration
No. 333-213956
Registration
No. 333-218420
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-165714
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-168970
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-172100
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-180144
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-188679
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-196740
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-213956
POST-EFFECTIVE
AMENDMENT NO. 2 TO FORM
S-8
REGISTRATION STATEMENT NO.
333-218420
UNDER
THE
SECURITIES ACT OF 1933
ANTHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
20-1852016
|
(State or other jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification Number)
|
J. Craig Thompson
Chief Executive Officer
Anthera Pharmaceuticals, Inc.
25801 Industrial Boulevard, Suite B
Hayward, California 94545
(510)
856-5600
(Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service)
AMENDED AND RESTATED 2010 STOCK OPTION AND INCENTIVE PLAN
2005 EQUITY INCENTIVE PLAN
2010 EMPLOYEE STOCK PURCHASE PLAN
2013 STOCK OPTION AND INCENTIVE PLAN
(Full Title of the Plans)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule
12b-2
of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
DEREGISTRATION OF UNSOLD SECURITIES
These Post-Effective Amendments are being filed to deregister unsold securities of Anthera Pharmaceuticals, Inc., a Delaware corporation
(
Anthera
or the
Registrant
) that were registered on the following Registration Statements on Form
S-8
(each, a
Registration Statemen
t, and collectively,
the
Registration Statements
) filed with the U.S. Securities and Exchange Commission (the
Commission
):
|
|
|
Registration Statement on Form
S-8
(No.
333-165714),
filed with the Commission on March 25, 2010, which registered 263,047 shares of
common stock, par value $0.001 (
Shares
) issuable pursuant to the terms of the Amended and Restated 2010 Stock Option and Incentive Plan (the
Option Plan
) and 1,313,944 Shares issuable pursuant to the terms of
the 2005 Equity Incentive Plan (the
Equity Incentive Plan
).
|
|
|
|
Registration Statement on Form
S-8
(No.
333-168970),
filed with the Commission on August 20, 2010, which registered 300,000 additional
Shares issuable pursuant to the Option Plan.
|
|
|
|
Registration Statement on Form
S-8
(No.
333-172100),
filed with the Commission on February 7, 2011, which registered 1,315,214
additional Shares issuable pursuant to the Option Plan and 250,000 Shares issuable pursuant to the Equity Incentive Plan.
|
|
|
|
Registration Statement on Form
S-8
(No.
333-180144),
filed with the Commission on March 15, 2012, which registered 1,637,521
additional Shares issuable pursuant to the Option Plan and 250,000 Shares issuable pursuant to the Equity Incentive Plan.
|
|
|
|
Registration Statement on Form
S-8
(No.
333-188679),
filed with the Commission on May 17, 2013, which registered 3,166,063 additional
Shares issuable pursuant to the Option Plan, 250,000 Shares issuable pursuant to the 2010 Employee Stock Purchase Plan (the
2010 ESPP
), and 14,000,000 Shares issuable pursuant to the 2013 Stock Option and Incentive Plan (the
2013 Plan
).
|
|
|
|
Registration Statement on Form
S-8
(No.
333-196740),
filed with the Commission on June 13, 2014, as amended, which registered 31,250
additional Shares issuable pursuant to the 2010 ESPP and 500,000 additional Shares issuable pursuant to the 2013 Plan.
|
|
|
|
Registration Statement on Form
S-8
(No.
333-213956),
filed with the Commission on October 4, 2016, which registered 3,390,818
additional Shares issuable pursuant to the 2013 Plan.
|
|
|
|
Registration Statement on Form
S-8
(No.
333-218420),
filed with the Commission on June 1, 2017, as amended, which registered 500,000
additional Shares issuable pursuant to the 2013 Plan and 31,250 Shares issuable pursuant to the 2010 ESPP.
|
The Registrant has delisted its
Common Stock from the NASDAQ Stock Market and is deregistering its Common Stock under Section 12(b) of the Securities and Exchange Act of 1934, as amended (the Exchange Act), through the filing of a Form 25 and Form 15 with the
Commission.
Accordingly, the Registrant hereby terminates the effectiveness of the Registration Statements and, in accordance with undertakings contained
in the Registration Statements to remove from registration by means of a post-effective amendment any of the securities that had been registered but remained unsold at the termination of the offering, removes from registration any and all securities
of the Registrant registered but unsold under the Registration Statements as of the date hereof.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, Anthera Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form
S-8
and has duly caused these Post-Effective Amendments to the Registration Statements described above to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Hayward, State of California, on July 20, 2018.
|
|
|
|
|
ANTHERA PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ May Liu
|
|
|
Name:
|
|
May Liu
|
|
|
Title:
|
|
Senior Vice President, Finance and Administration
|
No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance upon Rule
478 of the Securities Act.
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
過去 株価チャート
から 11 2024 まで 12 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
過去 株価チャート
から 12 2023 まで 12 2024